Tiziana life sciences to proceed with phase 2 clinical trial in patients with non-active secondary progressive multiple sclerosis (spms)

Fda provides positive feedback on intranasal foralumab program in patients with non-active spms fda provides positive feedback on intranasal foralumab program in patients with non-active spms
TLSA Ratings Summary
TLSA Quant Ranking